LAZARUS ROCHELLE B - 10 Jun 2022 Form 4 Insider Report for Organon & Co. (OGN)

Role: Director
Signature: /s/ Tarnetta V. Jones, as Attorney-in-Fact for Rochelle B. Lazarus
Issuer symbol: OGN
Transactions as of: 10 Jun 2022
Net transactions value: +$199,994
Form type: 4
Filing time: 14 Jun 2022, 19:34:22 UTC
Previous filing: 13 Jul 2021
Next filing: 11 Jul 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	OGN	Common Stock						458	10 Jun 2022	Direct	F1
holding	OGN	Common Stock						175	10 Jun 2022	By Spouse

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	OGN	Phantom Stock	Award	$199,994	+5,640	+63%	$35.46	14,638	10 Jun 2022	Common Stock	5,640		Direct	F2, F3, F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The number of shares of Organon & Co. ("Organon") common stock previously reported has been adjusted based on the finalization of certain calculations in connection with the separation of Organon from Merck & Co., Inc.
F2	Each phantom stock unit is an economic equivalent of one share of Organon common stock, or 1-for-1.
F3	Phantom stock units are granted under the Organon Non-Employee Director Savings Plan (the "Plan") and are payable in cash upon settlement after the reporting person's termination of service as a director pursuant to the terms of the Plan.
F4	Holdings include phantom stock acquired in dividend reinvestment transactions on September 13, 2021, December 16, 2021 and March 17, 2022.